ArticleTheranostics2022
ERK inactivation enhances stemness of NSCLC cells via promoting Slug-mediated epithelial-to-mesenchymal transition.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.4field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- microRNA-204 as a crucial cancer stem cell related miRNA inhibits stemness of gastric cancer by targeting CD44 and EPCAM.Journal of translational medicine · 2026Article
- JAK-STAT signaling pathway in cancer: from molecular mechanisms to clinical intervention.Molecular cancer · 2026Review
- Ginkgetin inhibits non-small cell lung cancer via the HSP90-AKT signaling pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Beyond immune surveillance: IFN-γ and PD-L1 as shapers of tumor plasticity in Non-Small Cell Lung Cancer (NSCLC).Frontiers in immunology · 2026Review
- BNIP3L/BNIP3-Mediated Mitophagy Contributes to the Maintenance of Ovarian Cancer Stem Cells.Journal of cellular and molecular medicine · 2025Article
- Unraveling the molecular-pathological characteristics and cellular complexity of the tumor immune microenvironment in metastatic non-small cell lung cancer.Cell communication and signaling : CCS · 2025Review
- Review
- Regulatory mechanisms of haptoglobin on particulate matter-induced epithelial-to-mesenchymal transition in bronchial epithelial cells.Journal of thoracic disease · 2024Article
- UBQLN4 promotes the proliferation and invasion of non-small cell lung cancer cell by regulating PI3K/AKT pathway.Journal of cancer research and clinical oncology · 2024Article
- Personalizing Therapy Outcomes through Mitogen-Activated Protein Kinase Pathway Inhibition in Non-Small Cell Lung Cancer.Biomedicines · 2024Review
- Cancer stem cells: advances in knowledge and implications for cancer therapy.Signal transduction and targeted therapy · 2024Review
- Interleukin-6 serves as a critical factor in various cancer progression and therapy.Medical oncology (Northwood, London, England) · 2024Review
- The SOX2/PDIA6 axis mediates aerobic glycolysis to promote stemness in non-small cell lung cancer cells.Journal of bioenergetics and biomembranes · 2024Article
- The thioredoxin system determines CHK1 inhibitor sensitivity via redox-mediated regulation of ribonucleotide reductase activity.Nature communications · 2024Article
- Chronic arsenic exposure induces malignant transformation of human HaCaT cells through both deterministic and stochastic changes in transcriptome expression.Toxicology and applied pharmacology · 2024Article
- Article
- Retinoblastoma: present scenario and future challenges.Cell communication and signaling : CCS · 2023Review
- SPDEF enhances cancer stem cell-like properties and tumorigenesis through directly promoting GALNT7 transcription in luminal breast cancer.Cell death & disease · 2023Article
- ALDH1A1 promotes PARP inhibitor resistance by enhancing retinoic acid receptor-mediated DNA polymerase θ expression.NPJ precision oncology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Shurui CaiDepartment of Radiation Oncology, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Na LiDepartment of Radiation Oncology, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Xuetao BaiDepartment of Radiation Oncology, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Lu LiuDepartment of Radiation Oncology, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Ananya BanerjeeDepartment of Radiation Oncology, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Kousalya LavudiDepartment of Radiation Oncology, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Xiaoli ZhangDepartment of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Jihe ZhaoBurnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL 32827, USA.
Monica VenereDepartment of Radiation Oncology, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Wenrui DuanDepartment of Human & Molecular Genetics, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA.
Junran ZhangDepartment of Radiation Oncology, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Meng X WelliverDepartment of Radiation Oncology, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Kai HeDepartment of Medical Oncology, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
Qi-En WangDepartment of Radiation Oncology, College of Medicine, The Ohio State University, Columbus, OH 43210, USA.
The Ohio State University · USUniversity of Central Florida · US
Funding
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3MAverting recurrent and resistant ovarian tumorsR01CA211175 · NCI · OHIO STATE UNIVERSITY · PI WANG, QIEN · 2017 to 2021
$2.3MMacrocyclic Peptidyl Inhibitors of NEMO-IKK InteractionR01CA234124 · NCI · OHIO STATE UNIVERSITY · PI PEI, DEHUA, WANG, QIEN · 2019 to 2023
$2.1MTargeting cholesterol metabolism and replication stress response in cancer therapyR01CA249198 · NCI · OHIO STATE UNIVERSITY · PI ZHANG, JUNRAN · 2021 to 2025
$1.8MB55 alpha deficiency as a therapeutic target in cancerR01CA240374 · NCI · OHIO STATE UNIVERSITY · PI ZHANG, JUNRAN · 2020 to 2024
$1.6MNCI NIH HHS P30 CA016058NCI NIH HHS R01 CA211175NCI NIH HHS R01 CA234124NCI NIH HHS R01 CA240374NCI NIH HHS R01 CA249198
Abstract
PubMed holds no abstract for this paper.
Indexed as
Carcinoma, Non-Small-Cell LungLung NeoplasmsMicroRNAsCell Line, TumorCell MovementGene Expression Regulation, NeoplasticHumansJanus KinasesMitogen-Activated Protein KinasesNeoplasm Recurrence, LocalProtein Kinase InhibitorsSignal TransductionSTAT Transcription FactorsTranscription FactorsJanus KinasesMicroRNAsMIRN204 microRNA, humanMitogen-Activated Protein KinasesProtein Kinase InhibitorsSTAT Transcription FactorsTranscription FactorsCancer stem celldedifferentiationEpithelial-to-mesenchymal transitionERKERK inhibitorNon-small cell lung cancerSlug
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.